Retatrutide

Retatrutide - sometimes called Triple-G - is a next-generation weight-loss compound that targets three receptors at once: GLP-1, GIP, and glucagon. By activating all three simultaneously, it aims to produce more powerful fat loss than current dual-agonist options. Early clinical trials have reported some of the largest weight-loss percentages seen yet in a pharmaceutical agent, which is why there is significant interest in it. The triple mechanism works by combining the appetite suppression of GLP-1, the metabolic enhancement of GIP, and the fat-burning and energy-expenditure effects of glucagon receptor activation. Together, these create a broad metabolic signal aimed at maximal fat reduction. Retatrutide is currently investigational - it has not yet received FDA approval. This means it is accessed only in supervised, monitored protocols and is not widely available. Evidence is categorized as emerging, based on clinical trial data that is still accumulating. It is given as a once-weekly subcutaneous injection, on the same day each week. Dose range in trials has been 1 to 12 mg, with careful titration to manage tolerability. GI side effects comparable to other GLP-1-class agents are expected during titration. Retatrutide should not be combined with other agents in this class - not semaglutide, tirzepatide, or liraglutide. It is not appropriate during pregnancy. Because human safety data is still developing, protocols are closely supervised. No compatible stacking partners are listed for retatrutide - it is generally used as a standalone agent. Exact dosing, titration, and monitoring schedule are set with a licensed provider in the PepDepo network at your consult.